Payment overview · 2025
General Payments
$59.81
4 reported records · 3 companies
Healthcare provider profile · identity verified
Dennis A Mesker, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WASHINGTON COURT HOUSE, OH · NPI 1467446146
Verified facts
What the public records show
CMS Open Payments records show Dennis A Mesker, MD received $59.81 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 46.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.01 | 46.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.00 | 30.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.80 | 23.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.81 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.01 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.01 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
272 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 839 | 254 |
| Levothyroxine Sodium | Levothyroxine Sodium | 486 | 132 |
| Omeprazole | Omeprazole | 473 | 141 |
| Lisinopril | Lisinopril | 447 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 122 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 373 | 117 |
| Gabapentin | Gabapentin | 335 | 105 |
| Losartan Potassium | Losartan Potassium | 322 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 311 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 299 | 96 |
| Eliquis | Apixaban | 272 | 60 |
| Metformin Hcl | Metformin Hcl | 214 | 63 |
| Trazodone Hcl | Trazodone Hcl | 212 | 64 |
| Furosemide | Furosemide | 204 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 56 |
| Alprazolam | Alprazolam | 186 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 61 |
| Metformin Hcl Er | Metformin Hcl | 171 | 56 |
| Fenofibrate | Fenofibrate Nanocrystallized | 170 | 53 |
| Potassium Chloride | Potassium Chloride | 165 | 57 |
| Carvedilol | Carvedilol | 158 | 53 |
| Sertraline Hcl | Sertraline Hcl | 149 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 44 |
| Simvastatin | Simvastatin | 142 | 44 |
| Ozempic | Semaglutide | 141 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 130 | 18 |
| Ezetimibe | Ezetimibe | 128 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 58 |
| Lorazepam | Lorazepam | 126 | 24 |
| Montelukast Sodium | Montelukast Sodium | 120 | 36 |
| Allopurinol | Allopurinol | 117 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 111 | 25 |
| Meloxicam | Meloxicam | 108 | 34 |
| Mounjaro | Tirzepatide | 108 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 28 |
| Alendronate Sodium | Alendronate Sodium | 99 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 24 |
| Clonazepam | Clonazepam | 92 | 17 |
| Buspirone Hcl | Buspirone Hcl | 88 | 26 |
| Tramadol Hcl | Tramadol Hcl | 88 | 19 |
| Glipizide Er | Glipizide | 87 | 27 |
| Atenolol | Atenolol | 85 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 22 |
| Chlorthalidone | Chlorthalidone | 72 | 22 |
| Famotidine | Famotidine | 71 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 17 |
| Spironolactone | Spironolactone | 63 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 49 |
| Bupropion Xl | Bupropion Hcl | 59 | 25 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Finasteride | Finasteride | 53 | 20 |
| Jardiance | Empagliflozin | 53 | 15 |
| Farxiga | Dapagliflozin Propanediol | 51 | 17 |
| Ibuprofen | Ibuprofen | 51 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Clonidine Hcl | Clonidine Hcl | 47 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 20 |
| Donepezil Hcl | Donepezil Hcl | 45 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 12 |
| Meclizine Hcl | Meclizine Hcl | 43 | 16 |
| Prednisone | Prednisone | 43 | 31 |
| Synthroid | Levothyroxine Sodium | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 18 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 18 |
| Temazepam | Temazepam | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Glipizide | Glipizide | 36 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 28 |
| Topiramate | Topiramate | 34 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 11 |
| Nitroglycerin | Nitroglycerin | 32 | 17 |
| Colchicine | Colchicine | 31 | 12 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Cefdinir | Cefdinir | 29 | 25 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Fentanyl | Fentanyl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nystatin | Nystatin | 21 | 15 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.81 · 4 records | PFIZER INC. | NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error